Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$107 Mln
Revenue (TTM)
$87 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.9 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.8
Industry P/E
28.02
EV/EBITDA
-6.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$1.1
EPS
$-0.6
Face value
--
Shares outstanding
12,406,900
CFO
$-1,245.55 Mln
EBITDA
$-932.67 Mln
Net Profit
$-1,757.19 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
| -39.0 | -18.4 | -36.8 | -50.2 | -45.3 | -52.2 | -26.2 |
|
BSE Sensex
| 5.3 | 0.4 | 9.2 | 6.6 | 17.1 | 18.9 | 11.7 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
| 65.4 | -75.2 | -83.3 | -20.5 | -21.2 | -34.3 | -44.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nektar Therapeutics (NKTR)
|
8.5 | 106.8 | 87.3 | -133.0 | -116.0 | -424.9 | -- | 7.8 |
| 17.7 | 4,328.3 | 459.4 | 206.8 | 25.6 | 68.3 | 21.6 | 11.3 | |
| 7.8 | 3,640.5 | 2,830.2 | -13.1 | 11.5 | -- | -- | 86.1 | |
| 100.7 | 5,065.9 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 95.2 | |
| 55.0 | 10,547.7 | 2,937.8 | 523.9 | 23.2 | 9.3 | 20.4 | 1.9 | |
| 41.7 | 7,923.7 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 71.4 | 7,569.5 | 685.5 | 132.9 | 15.6 | 20.1 | 62.1 | 11.1 | |
| 13.5 | 6,684.9 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.9 | 1.0 | |
| 83.4 | 4,123.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.4 | 2.3 | |
| 8.9 | 10,410.5 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T... (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. Read more
CEO, President & Director
Mr. Howard W. Robin
CEO, President & Director
Mr. Howard W. Robin
Headquarters
San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Nektar Therapeutics (NKTR) stood at $ 327 Mln as on 31-Mar-25
The share price of Nektar Therapeutics (NKTR) is $8.51 (NASDAQ) as of 20-Jun-2025 16:06 EDT. Nektar Therapeutics (NKTR) has given a return of -45.32% in the last 3 years.
Nektar Therapeutics (NKTR) has a market capitalisation of $ 107 Mln as on 20-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Nektar Therapeutics (NKTR) is 7.78 times as on 20-Jun-2025, a 64% premium to its peers’ median range of 4.74 times.
Since, TTM earnings of Nektar Therapeutics (NKTR) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Nektar Therapeutics (NKTR) and enter the required number of quantities and click on buy to purchase the shares of Nektar Therapeutics (NKTR).
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
The CEO & director of Mr. Howard W. Robin. is Nektar Therapeutics (NKTR), and CFO & Sr. VP is Mr. Howard W. Robin.
There is no promoter pledging in Nektar Therapeutics (NKTR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,059
|
|
|
1,029
|
|
|
762
|
|
|
761
|
|
|
676
|
|
|
507
|
|
|
433
|
|
|
414
|
|
|
368
|
| Nektar Therapeutics (NKTR) | Ratios |
|---|---|
|
Return on equity(%)
|
-424.9
|
|
Operating margin(%)
|
-115.96
|
|
Net Margin(%)
|
-152.49
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Nektar Therapeutics (NKTR) was $0 Mln.
$-0.10
(
